tbuckley/cabot-search huggingface dataset:
Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease
Authors: Ivan Weisser, Kara Eckberg, Stephen D'Amico, Daniel Buttram, Karam Aboudehen
Journal: Journal of the American Society of Nephrology (2023)

Significance Statement Long noncoding RNAs (lncRNAs) are a class of nonprotein coding RNAs with pivotal functions in development and disease. They have emerged as an exciting new drug target category for many common conditions. However, the role of lncRNAs in autosomal dominant polycystic kidney disease (ADPKD) has been understudied. This study provides evidence implicating a lncRNA in the pathogenesis of ADPKD. We report that Hoxb3os is downregulated in ADPKD and regulates mammalian target of rapamycin (mTOR)/Akt pathway in the in vivo mouse kidney. Ablating the expression of Hoxb3os in mouse polycystic kidney disease (PKD) activated mTOR complex 2 (mTORC2) signaling and exacerbated the cystic phenotype. The results from our study provide genetic proof of concept for future studies that focus on targeting lncRNAs as a treatment option in PKD. Background ADPKD is a monogenic disorder characterized by the formation of kidney cysts and is primarily caused by mutations in two genes, PKD1 and PKD2 . Methods In this study, we investigated the role of lncRNA Hoxb3os in ADPKD by ablating its expression in the mouse. Results Hoxb3os -null mice were viable and had grossly normal kidney morphology but displayed activation of mTOR/Akt signaling and subsequent increase in kidney cell proliferation. To determine the role of Hoxb3os in cystogenesis, we crossed the Hoxb3os -null mouse to two orthologous Pkd1 mouse models: Pkhd1/Cre; Pkd1 F/F (rapid cyst progression) and Pkd1 RC/RC (slow cyst progression). Ablation of Hoxb3os exacerbated cyst growth in both models. To gain insight into the mechanism whereby Hoxb3os inhibition promotes cystogenesis, we performed western blot analysis of mTOR/Akt pathway between Pkd1 single-knockout and Pkd1 - Hoxb3os double-knockout (DKO) mice. Compared with single-knockout, DKO mice presented with enhanced levels of total and phosphorylated Rictor. This was accompanied by increased phosphorylation of Akt at Ser 473 , a known mTORC2 effector site. Physiologically, kidneys from DKO mice displayed between 50% and 60% increase in cell proliferation and cyst number. Conclusions The results from this study indicate that ablation of Hoxb3os in mouse PKD exacerbates cystogenesis and dysregulates mTORC2.
GlcNac produced by the gut microbiome enhances host influenza resistance by modulating NK cells
Authors: Xiaotong Hu, Xiaolu Sun, Ya Zhao, Changjie Iv, Xiaomei Sun, Meilin Jin, Qiang Zhang
Journal: Gut Microbes (2023)

Microbiota are known to modulate the host response to influenza infection, but the mechanisms remain largely unknown. Gut metabolites are the key mediators through which gut microbes play anti-influenza effect. Transferring fecal metabolites from mice with high influenza resistance into antibiotic-treated recipient mice conferred resistance to influenza infections. By comparing the metabolites of different individuals with high or low influenza resistance, we identified and validated N-acetyl-D-glucosamine (GlcNAc) and adenosine showed strong positive correlations with influenza resistance and exerted anti-influenza effects in vivo or in vitro, respectively. Especially, GlcNAc mediated the anti-influenza effect by increasing the proportion and activity of NK cells. Several gut microbes, including Clostridium sp., Phocaeicola sartorii, and Akkermansia muciniphila, were positively correlated with influenza resistance, and can upregulate the level of GlcNAc in the mouse gut by exogenous supplementation. Subsequent studies confirmed that administering a combination of the three bacteria to mice via gavage resulted in similar modulation of NK cell responses as observed with GlcNAc. This study demonstrates that gut microbe-produced GlcNAc protects the host against influenza by regulating NK cells, facilitating the elucidation of the action mechanism of gut microbes mediating host influenza resistance.
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
Authors: Allison M Bock, Jennifer J Gile, Melissa C Larson, Kittika Poonsombudlert, Reema K Tawfiq, Seth Maliske, Matthew J Maurer, Brian F Kabat, Jonas Paludo, David J Inwards, Sabarish Ayyappan, Brian K Link, Stephen M Ansell, Thomas M Habermann, Thomas E Witzig, Grzegorz S Nowakowski, James R Cerhan, Umar Farooq, Yucai Wang
Journal: Blood Cancer Journal (2023)

Abstract Over the last two decades, the frontline therapy for mantle cell lymphoma (MCL) has evolved. However, the impact of subsequent lines of therapy on survival outcomes has not been well characterized. In this study, we investigated the treatment patterns and survival outcomes in patients with relapsed/refractory (R/R) MCL treated with second-line (2 L) therapy. Adult patients with newly diagnosed MCL from 2002 to 2015 were enrolled in a prospective cohort study. Clinical characteristics, 2 L treatment details, and outcomes were compared between patients who received 2 L treatment between 2003–2009 (Era 1), 2010–2014 (Era 2), and 2015–2021 (Era 3). 2 L treatment was heterogenous in all eras, and there was a substantial shift in the pattern of 2 L therapy over time. The estimated 2-year EFS rate was 21% (95% CI, 13–35), 40% (95% CI, 30–53), and 51% (95% CI, 37–68) in Era 1–3 respectively, and the 5-year OS rate was 31% (95% CI, 21–45), 37% (95% CI, 27–50), and 67% (95% CI, 54–83) in Era 1–3, respectively. These results provide real-world evidence on evolving treatment patterns of 2 L therapy based on the era of relapse. The changes in 2 L treatment correlated with improved EFS and OS, suggesting that treatment advances are associated with improved outcomes in patients with R/R MCL.
Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis
Authors: Nikolas H. Stoecklein, Georg Fluegen, Rosa Guglielmi, Rui P.L. Neves, Thilo Hackert, Emrullah Birgin, Stefan A. Cieslik, Monica Sudarsanam, Christiane Driemel, Guus van Dalum, André Franken, Dieter Niederacher, Hans Neubauer, Tanja Fehm, Jutta M. Rox, Petra Böhme, Lena Häberle, Wolfgang Göring, Irene Esposito, Stefan A. Topp, Frank A.W. Coumans, Jürgen Weitz, Wolfram T. Knoefel, Johannes C. Fischer, Ulrich Bork, Nuh N. Rahbari
Journal: Molecular Cancer (2023)

Abstract The limited sensitivity of circulating tumor cell (CTC) detection in pancreatic adenocarcinoma (PDAC) stems from their extremely low concentration in the whole circulating blood, necessitating enhanced detection methodologies. This study sought to amplify assay-sensitivity by employing diagnostic leukapheresis (DLA) to screen large blood volumes. Sixty patients were subjected to DLA, with a median processed blood volume of ~ 2.8 L and approximately 5% of the resulting DLA-product analyzed using CellSearch (CS). Notably, DLA significantly increased CS-CTC detection to 44% in M0-patients and 74% in M1-patients, yielding a 60-fold increase in CS-CTC enumeration. DLA also provided sufficient CS-CTCs for genomic profiling, thereby delivering additional genomic information compared to tissue biopsy samples. DLA CS-CTCs exhibited a pronounced negative prognostic impact on overall survival (OS), evidenced by a reduction in OS from 28.6 to 8.5 months (univariate: p = 0.002; multivariable: p = 0.043). Additionally, a marked enhancement in sensitivity was achieved (by around 3-4-times) compared to peripheral blood (PB) samples, with positive predictive values for OS being preserved at around 90%. Prognostic relevance of CS-CTCs in PDAC was further validated in PB-samples from 228 PDAC patients, consolidating the established association between CTC-presence and reduced OS (8.5 vs. 19.0 months, p &lt; 0.001). In conclusion, DLA-derived CS-CTCs may serve as a viable tool for identifying high-risk PDAC-patients and aiding the optimization of multimodal treatment strategies. Moreover, DLA enables comprehensive diagnostic profiling by providing ample CTC material, reinforcing its utility as a reliable liquid-biopsy approach. This high-volume liquid-biopsy strategy presents a potential pathway for enhancing clinical management in this malignancy.
Deep phenotyping of p.(<scp>V142I</scp>)‐associated variant transthyretin amyloid cardiomyopathy: Distinct from wild‐type transthyretin amyloidosis?
Authors: Yousuf Razvi, Adam Ioannou, Rishi K. Patel, Liza Chacko, Nina Karia, Mattia Riefolo, Aldostefano Porcari, Muhammad Umaid Rauf, Neasa Starr, Sashiananthan Ganesananthan, Iona Blakeney, Nandita Kaza, Stefano Filisetti, Roos Eline Bolhuis, Dorota Rowczenio, Janet Gilbertson, David Hutt, Shameem Mahmood, Helen J. Lachmann, Ashutosh D. Wechalekar, Tushar Kotecha, Daniel S. Knight, John G. Coghlan, Aviva Petrie, Carol J. Whelan, Lucia Venneri, Ana Martinez‐Naharro, Phillip Hawkins, Marianna Fontana, Julian D. Gillmore
Journal: European Journal of Heart Failure (2023)

Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasingly recognized cause of heart failure. A total of 3–4% of individuals of African descent carry a TTR gene mutation encoding the p.(V142I) variant, a powerful risk factor for development of variant ATTR‐CM (ATTRv‐CM); this equates to 1.6 million carriers in the United States. We undertook deep phenotyping of p.(V142I)‐ATTRv‐CM and comparison with wild‐type ATTR‐CM (ATTRwt‐CM). Methods and results A retrospective study of 413 patients with p.(V142I) ATTRv‐CM who attended the UK National Amyloidosis Centre (NAC) was conducted. Patients underwent evaluation at time of diagnosis, including clinical, echocardiography, and biomarker analysis; a subgroup had cardiac magnetic resonance (CMR) imaging. A total of 413 patients with ATTRwt‐CM, matched for independent predictors of prognosis (age, NAC Stage, decade of first presentation), were used as a comparator group. At time of diagnosis, patients with ATTRv‐CM had significant functional impairment by New York Heart Association classification (NHYA class ≥ III; 38%) and 6‐min walk test distance (median 276 m). Median 5‐year survival in ATTRv‐CM patients was 31 versus 59 months in matched patients with ATTRwt‐CM ( p &lt; 0.001). Patients with ATTRv‐CM had significant impairment of functional parameters by echocardiography including biventricular impairment, high burden of regurgitant valvular disease and low cardiac output. Multivariable analysis revealed the prognostic importance of right ventricular dysfunction. CMR and histological analysis revealed myocyte atrophy and widespread myocardial infiltration in ATTRv‐CM. Conclusion p.(V142I)‐ATTRv‐CM has an aggressive phenotype characterized by myocyte loss and widespread myocardial infiltration which may account for frequent biventricular failure and poor prognosis in this ATTR‐CM genotypic subgroup.
Association of neighbourhood‐level material deprivation with adverse outcomes and processes of care among patients with heart failure in a single‐payer healthcare system: A population‐based cohort study
Authors: David Bobrowski, Andrew Dorovenis, Husam Abdel‐Qadir, Candace D. McNaughton, Rea Alonzo, Jiming Fang, Peter C. Austin, Jacob A. Udell, Cynthia A. Jackevicius, David A. Alter, Clare L. Atzema, R. Sacha Bhatia, Gillian L. Booth, Andrew C.T. Ha, Sharon Johnston, Irfan Dhalla, Moira K. Kapral, Harlan M. Krumholz, Idan Roifman, Harindra C. Wijeysundera, Dennis T. Ko, Karen Tu, Heather J. Ross, Michael J. Schull, Douglas S. Lee
Journal: European Journal of Heart Failure (2023)

We studied the association between neighbourhood material deprivation, a metric estimating inability to attain basic material needs, with outcomes and processes of care among incident heart failure patients in a universal healthcare system.
Fake IDs? Widespread misannotation of DNA transposons as a general transcription factor
Authors: Nozhat T. Hassan, David L. Adelson
Journal: Genome biology (2023)

Abstract Accurate annotation of genes and transposable elements (TEs) is vital for understanding genomes, but current annotation pipelines often misannotate TEs as genes. This study reveals how the general transcription factor II-I repeat domain-containing protein 2 (GTF2IRD2) erroneously annotated DNA transposons in non-mammalian species, as it contains a 3′ fused hAT transposase domain. We also demonstrate the generality of this problem by identifying misannotated TEs as genes in other vertebrate genomes. Such misannotations can lead to errors in phylogenetic analyses and wasted time for investigators. The study proposes adding a final TE-check to gene annotation pipelines to mitigate this problem.
Post‐Graphene 2D Materials: Structures, Properties, and Cancer Therapy Applications
Authors: Fei Kuang, Tiankun Hui, Yingjie Chen, Meng Qiu, Xiang Gao
Journal: Advanced Healthcare Materials (2023)

Cancer is one of the most serious diseases challenging human health and life span. Cancer has claimed millions of lives worldwide. Early diagnosis and effective treatment of cancer are very important for the survival of patients. In recent years, 2D nanomaterials have shown great potential in the development of anticancer treatment by combining their inherent physicochemical properties after surface modification. 2D nanomaterials have attracted great interest due to their unique nanosheet structure, large surface area, and extraordinary physicochemical properties. This article reviews the advantages and application status of emerging 2D nanomaterials for targeted tumor synergistic therapy compared with traditional therapeutic strategies. In order to investigate novel potential anticancer strategies, this paper focuses on the surface modification, cargo delivery capability, and unique optical properties of emerging 2D nanomaterials. Finally, the current problems and challenges in cancer treatment are summarized and prospected.
ARPA-H Funds Two “Manhattan Projects” for Cancer
Journal: Cancer Discovery (2023)

Abstract The Advanced Research Projects Agency for Health (ARPA-H) recently announced two major cancer-related funding awards. One at Rice University will focus on implanting a small device that continuously monitors a patient's cancer and adjusts immunotherapy doses in real time. Another is going to Emory University to develop new ways to enhance the body's immune response toward therapies for cancers, autoimmune disorders, and infectious diseases.
Factors affecting the GABAergic synapse function in Alzheimer’s disease: Focus on microRNAs
Authors: Jazmin Rivera, Bhupender Sharma, Melissa M. Torres, Subodh Kumar
Journal: Ageing Research Reviews (2023)

Alzheimer's disease (AD) is a progressive neurological disease characterized by the loss of cognitive function, confusion, and memory deficit. Accumulation of abnormal proteins, amyloid beta (Aß), and phosphorylated Tau (p-tau) forms plaques and tangles that deteriorate synapse function, resulting in neurodegeneration and cognitive decline in AD. The human brain is composed of different types of neurons and/or synapses that are functionally defective in AD. The GABAergic synapse, the most abundant inhibitory neuron in the human brain was found to be dysfunctional in AD and contributes to disrupting neurological function. This study explored the types of GABA receptors associated with neurological dysfunction and various biological and environmental factors that cause GABAergic neuron dysfunction in AD, such as Aβ, p-tau, aging, sex, astrocytes, microglia, APOE, mental disorder, diet, physical activity, and sleep. Furthermore, we explored the role of microRNAs (miRNAs) in the regulation of GABAergic synapse function in neurological disorders and AD states. We also discuss the molecular mechanisms underlying GABAergic synapse dysfunction with a focus on miR-27b, miR-30a, miR-190a/b, miR-33, miR-51, miR-129-5p, miR-376-3p, miR-376c, miR-30b and miR-502-3p. The purpose of our article is to highlight the recent research on miRNAs affecting the regulation of GABAergic synapse function and factors that contribute to the progression of AD.
Inducing in situ M2 macrophage polarization to promote the repair of bone defects via scaffold-mediated sustained delivery of luteolin
Authors: Yan Hu, Lixi Tang, Zheng Wang, Honghan Yan, Xinzeyu Yi, Huimin Wang, Liya Ma, Changying Yang, Jiabing Ran, Aixi Yu
Journal: Journal of Controlled Release (2023)
Cannabidiol - Help and hype in targeting mucosal diseases
Authors: Md Moniruzzaman, Taskeen Iqbal Janjua, Jennifer H. Martin, Jakob Begun, Amirali Popat
Journal: Journal of Controlled Release (2023)

Cannabidiol (CBD) is one of the most commonly utilised phytocannabinoids due to its non-psychoactive and multiple potential therapeutic properties and its non-selective pharmacology. Recent studies have demonstrated efficacy of CBD in some types of drug resistant epilepsies in combination with other therapies; comparative efficacy to other agents or placebo has been hoped for anxiety, chronic pain, and inflammatory disorders based on animal data. Although CBD products are generally treated as a restricted substance, these are being eased, partially in response to significant growth in CBD product usage and increased production but more due to emerging evidence about its safety and pharmacological properties. Currently, only one CBD product (Epidiolex®) has been approved by the Australian Therapeutic Goods Administration and US Food and Drug Administration. CBD has demonstrated promise in alleviating gut and lung diseases in vitro; however, its physicochemical properties pose a significant barrier to achieving pharmacological effects in in vivo and clinical trials. Improving CBD formulations and delivery methods using technologies including self-emulsifying emulsion, nano and micro particles could overcome these shortfalls and improve its efficacy. This review focuses on the therapeutic potential of CBD in gastrointestinal and lung diseases from the available in vitro, in vivo, and clinical research. We report on identified research gaps and obstacles in the development of CBD-based therapeutics, including novel delivery methods.
Impact of Clinical Demands on the Educational Mission in Hospital Medicine at 17 Academic Medical Centers
Authors: Vishruti Patel, Angela Keniston, Lauren McBeth, Sagarika Arogyaswamy, Catherine Callister, Khooshbu Dayton, Neelam Mistry, Sarah Mann, Marisha Burden
Journal: Annals of Internal Medicine (2023)

Clinical growth is outpacing the growth of traditional educational opportunities at academic medical centers (AMCs).To understand the impact of clinical growth on the educational mission for academic hospitalists.Qualitative study using semistructured interviews that were analyzed using a mixed inductive and deductive method at the semantic level.Large AMCs across the United States that experienced clinical growth in the past 5 years.Division heads, section heads, and other hospital medicine (HM) leaders who oversaw and guided academic and clinical efforts of HM programs.Themes and subthemes.From September 2021 to January 2022, HM leaders from 17 AMCs participated in the interviews, and 3 key themes emerged. First, AMCs' disproportionate clinical growth highlighted the tension between clinical and educational missions. This included a mismatch in supply and demand for traditional teaching time, competing priorities, and clinical growth being seen as both an opportunity and a threat. Second, amid the shifting landscape of high clinical demands and evolving educational opportunities, hospitalists still strongly prefer traditional teaching. To address this mismatch, HM groups have had to alter recruitment strategies and create innovative solutions to help build academic careers. Third, participants noted a need to reimagine the role and identity of an academic hospitalist, emphasizing tailored career pathways and educational roles spanning well beyond traditional house staff teaching teams.The study focused on large AMCs.Although HM groups have implemented many creative strategies to address clinical growth and keep education front and center, challenges remain, particularly heavy clinical workloads and a continued dilution of traditional teaching opportunities.Society of Hospital Medicine Student Scholar Grant.
Efficacy of Acupuncture for Chronic Spontaneous Urticaria
Authors: Hui Zheng, Xian-Jun Xiao, Yun-Zhou Shi, Lei-Xiao Zhang, Wei Cao, Qian-Hua Zheng, Feng Zhong, Ping-Sheng Hao, Ying Huang, Ming-Ling Chen, Wei Zhang, Si-Yuan Zhou, Yan-Jun Wang, Chuan Wang, Li Zhou, Xiao-Qin Chen, Zuo-Qin Yang, Zi-Hao Zou, Ling Zhao, Fan-Rong Liang, Ying Li
Journal: Annals of Internal Medicine (2023)

The effectiveness of acupuncture for patients with chronic spontaneous urticaria (CSU), reported in a few small-scale studies, is not convincing.
MO62-1 Prediction of early lung cancer development using whole lung texture analysis from LDCT
Authors: Wei-Ming Huang, Chia-Yi Liu, Hsuan-Yu Chen, Ya-Hsuan Chang, Sheng-Hsiung Yang, Wen-Jui Wu, Chia-Te Yen, Yen-Ting Chen, Chao-Hsien Chen, Pan-Chyr Yang, Kuang-Chun Hu, Chun-Ho Yun
Journal: Annals of Oncology (2023)
MO49-5 Efficacy and safety of R-THP-COP therapy for elderly patients with untreated diffuse large B-cell lymphoma
Authors: Daishi Kato, Tsutomu Kobayashi, Rina Nakayama, Takahisa Nakamura, Muneo Ohshiro, Mio Sugitani, Yosuke Matsumoto, Toshiki Iwai, Hitoji Uchiyama
Journal: Annals of Oncology (2023)
MO55-5 Impact of tumor genomic alterations on development of cancer cachexia in patients with advanced non-small cell lung cancer
Authors: Hiroyuki Fujii, Tatsuya Yoshida, Masayuki Shirasawa, Kazushi Fujimoto, Takaaki Mizuno, Kuniko Sunami, Takafumi Koyama, Noriko Motoi, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Journal: Annals of Oncology (2023)
P10-1 Analysis of thromboembolism and prognosis in metastatic pancreatic cancer: A secondary analysis of Tokushukai REAl-world Data project 03-S1
Authors: Rai Shimoyama, Yoshinori Imamura, Kiyoaki Uryu, Takahiro Mase, Yoshiaki Fujimura, Maki Hayashi, Megu Ohtaki, Keiko Ohtani, Nobuaki Shinozaki, Hironobu Minami
Journal: Annals of Oncology (2023)
MO65-2 High intramuscular adipose tissue content is a favorable prognostic factor in patients with advanced gastric cancer treated with nivolumab
Authors: Toshimitsu Tanaka, Keisuke Miwa, Yasutaka Shimotsuura, Sachiko Nagasu, Hirona Shigyou, Keisuke Hirota, Shunji Kamiya, Takumi Kawaguchi
Journal: Annals of Oncology (2023)
MO68-4 A chemoproteoinformatics approach demonstrates that aspirin increases sensitivity to MEK inhibition by directly binding to RPS5
Authors: Shogen Boku, Motoki Watanabe, Kaito Kobayashi, Yoichi Kurumida, Mamiko Sukeno, Mitsuharu Masuda, Katsura Mizushima, Chikage Kato, Yosuke Iizumi, Kiichi Hirota, Yuji Naito, Michihiro Mutoh, Toshiyuki Sakai, Tomoshi Kameda
Journal: Annals of Oncology (2023)
P17-6 Report of the Cancer Salon at Jichi Medical University Hospital – the 8th report
Authors: Rie Yamamoto, Kaori Komatsuzaki, Yoshiko Kojima, Miwako Inada, Yumi Oeda, Akiko Nakayama, Saori Chiba, Masaaki Inoue, Kiyoe Sato, Hironori Yamaguchi
Journal: Annals of Oncology (2023)
P57-2 Retrospective study of second-line FOLFOX versus S1 for advanced biliary tract cancer
Authors: Akihiko Chida, Yasuo Hamamoto, Eiichiro So, Satoko Shimizu, Shotaro Kishimoto, Sara Horie, Yuki Saito, Keitaro Shimozaki, Kazuhiro Togasaki, Kai Tsugaru, Kenro Hirata, Hideyuki Hayashi, Takanori Kanai
Journal: Annals of Oncology (2023)
P26-9 Clinical outcome of nivolumab and ipilimumab in untreated advanced non-small cell lung cancer patients
Authors: Akira Sugimoto, Hiroyasu Kaneda, Hiroaki Nagamine, Kenji Nakahama, Koichi Ogawa, Yoshiya Matsumoto, Kenji Sawa, Yoko Tani, Shigeki Mitsuoka, Tatsuo Kimura, Tomoya Kawaguchi
Journal: Annals of Oncology (2023)
P55-2 BRCA2 reversion mutations as a resistance mechanism of olaparib in patients with BRCA2-associated mCRPC
Authors: Kohji Takemura, Ayumi Abe, Taro Yamanaka, Erisa Toda, Haruka Kono, Haruka Ozaki, Masahiro Kuno, Hiroki Okumura, Kazumasa Yamamoto, Shogo Watanabe, Rika Kizawa, Takeshi Yamaguchi, Marina Kobayashi, Akinari Sekine, Kazushige Sakaguchi, Yuko Tanabe, Koichi Suyama, Shinji Urakami, Masami Arai, Yuji Miura
Journal: Annals of Oncology (2023)